RAPT Therapeutics, Inc. (RAPT) Cash from Financing Activities (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Cash from Financing Activities for 5 consecutive years, with $143.1 million as the latest value for Q4 2024.
- Quarterly Cash from Financing Activities rose 31147.82% to $143.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $152.9 million through Dec 2024, up 10463.37% year-over-year, with the annual reading at $152.9 million for FY2024, 10463.37% up from the prior year.
- Cash from Financing Activities hit $143.1 million in Q4 2024 for RAPT Therapeutics, up from $701000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $143.1 million in Q4 2024 to a low of $106000.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged $26.4 million across 5 years, with a median of $864000.0 in 2020.
- Biggest five-year swings in Cash from Financing Activities: tumbled 99.39% in 2023 and later soared 31147.82% in 2024.
- Year by year, Cash from Financing Activities stood at $4.6 million in 2020, then tumbled by 86.82% to $601000.0 in 2021, then skyrocketed by 12438.94% to $75.4 million in 2022, then crashed by 99.39% to $458000.0 in 2023, then skyrocketed by 31147.82% to $143.1 million in 2024.
- Business Quant data shows Cash from Financing Activities for RAPT at $143.1 million in Q4 2024, $701000.0 in Q2 2024, and $9.0 million in Q1 2024.